NCT04159532 is a Phase 4 clinical trial of MAG-EPA/MAG-DHA in Healthy Adults, sponsored by SCF Pharma.

Who is sponsoring NCT04159532?

NCT04159532 is sponsored by SCF Pharma.

What drugs are being tested in NCT04159532?

Interventions in NCT04159532: MAG-EPA/MAG-DHA, TG-EPA/TG-DHA, EE-EPA/EE-DHA.

What condition does NCT04159532 study?

NCT04159532 studies Healthy Adults.

Is NCT04159532 still recruiting?

NCT04159532 is currently completed. Last updated 29 April 2021.

Last reviewed 2021-04-29 · How we verify

NCT04159532

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA)

Completed Phase 4 Last updated 29 April 2021

What this trial tests

Phase 4 trial testing MAG-EPA/MAG-DHA in Healthy Adults in 36 participants. Completed in 25 February 2021.

Timeline

18 December 2019

Primary endpoint
25 February 2021

25 February 2021

Quick facts

Lead sponsor	SCF Pharma
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	36
Start date	18 December 2019
Primary completion	25 February 2021
Estimated completion	25 February 2021
Sites	1 location across Canada

Drugs / interventions tested

MAG-EPA/MAG-DHA
TG-EPA/TG-DHA
EE-EPA/EE-DHA

Conditions studied

Healthy Adults — all drugs for Healthy Adults →

Sponsor

SCF Pharma

Who can join

19 and older, any sex, with Healthy Adults. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study aims at comparing the bioavailability of three different formulations of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The three formulations are ethyl ester (EE), triglyceride (TG) and monoglyceride (MAG). Thirty six (36) subjects will be divided in three groups of twelve subjects each equally divided in two study sites. Each group will be taking one of the three different formulations of EPA+DHA at a daily dose of 1.5g for a period of 12 weeks. Bioavailability will be measured through omega-3 index (total content of EPA + DHA in red blood cell membranes) at baseline and every four weeks during treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Adults

Currently open trials in the same condition.

NCT07454551 — The Comparison of Different Passive Warm-Up Methods Prior to Exercise · NA · recruiting
NCT07431853 — A Study to Learn About mRNA Vaccines Against Influenza in Adults · Phase 2 · recruiting
NCT07362550 — Effects of 12-Week Balanced Diet on Body Composition & Metabolic Parameters in Twins · NA · recruiting
NCT07284173 — A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Health · Phase 1 · active not recruiting
NCT07518758 — Acute Effect of Polyphenols Supplementation on Endothelial Function and Exercise Related Markers, in Physically Active H · NA · active not recruiting

Other SCF Pharma trials

Trials by the same sponsor.

NCT06155513 — Omega-3 Monoglyceride Based Topic Products as Skin Prebiotics for Eczema · NA · recruiting
NCT06219213 — Glyceryl Eicosapentaenoate Based Topic Products As an Irritant-free Cream and Serum for Hydration of Sensitive Skin · NA · recruiting
NCT04897893 — Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+. · Phase 4 · completed
NCT05161702 — Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC). · recruiting
NCT03159507 — Effect of Omega-3 Index on Cellular Metabolism and Quality of Life · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04159532 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SCF Pharma
Last refreshed: 29 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04159532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing